Добірка наукової літератури з теми "FDA-approved drug"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "FDA-approved drug".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "FDA-approved drug"
Gould, Stephen J. "AIDS and FDA Drug-Approved Policy:." Journal of Health & Social Policy 2, no. 2 (February 21, 1991): 39–46. http://dx.doi.org/10.1300/j045v02n02_03.
Повний текст джерелаVokinger, Kerstin Noëlle, and Aaron S. Kesselheim. "Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU." BMJ Open 9, no. 10 (October 2019): e028634. http://dx.doi.org/10.1136/bmjopen-2018-028634.
Повний текст джерелаZhong, Hao, Ging Chan, Yuanjia Hu, Hao Hu, and Defang Ouyang. "A Comprehensive Map of FDA-Approved Pharmaceutical Products." Pharmaceutics 10, no. 4 (December 6, 2018): 263. http://dx.doi.org/10.3390/pharmaceutics10040263.
Повний текст джерелаEzeife, Doreen Anuli, Patricia Tang, Daniel Yick Chin Heng, and Stephen Welch. "Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6082. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6082.
Повний текст джерелаSaberian, Nafiseh, Azam Peyvandipour, Michele Donato, Sahar Ansari, and Sorin Draghici. "A new computational drug repurposing method using established disease–drug pair knowledge." Bioinformatics 35, no. 19 (March 6, 2019): 3672–78. http://dx.doi.org/10.1093/bioinformatics/btz156.
Повний текст джерелаHershman, Dawn L., Alfred I. Neugut, Donna Buono, Catherine A. Richards, Sherry A. Glied, and Jason Dennis Wright. "Off-label and compendia use of chemotherapy in patients with metastatic cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 6509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6509.
Повний текст джерелаNair, Aathira Sujathan, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim, and Bijo Mathew. "FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years." Processes 10, no. 10 (October 11, 2022): 2054. http://dx.doi.org/10.3390/pr10102054.
Повний текст джерелаKlasmeier, Coleen, and Martin H. Redish. "Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech Protection." American Journal of Law & Medicine 37, no. 2-3 (June 2011): 315–57. http://dx.doi.org/10.1177/009885881103700206.
Повний текст джерелаLosben, Nancy L. "2020: A Record Year for Drug Approvals." Senior Care Pharmacist 36, no. 4 (April 1, 2021): 174–75. http://dx.doi.org/10.4140/tcp.n.2021.174.
Повний текст джерелаRizzo, Carla, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi, and Antonio Palumbo Piccionello. "FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022." International Journal of Molecular Sciences 24, no. 9 (April 23, 2023): 7728. http://dx.doi.org/10.3390/ijms24097728.
Повний текст джерелаДисертації з теми "FDA-approved drug"
MASSARO, DAMIANO SERGIO. "Drug Reprofile for Friedreich’s Ataxia: Screening of an FDA-Approved Drugs Library searching for small molecules that increase Frataxin." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2015. http://hdl.handle.net/2108/203080.
Повний текст джерелаCapua, Christopher James. "Comparative Cytotoxicity of an FDA-approved Cancer Drug to Extracts of Atriplex confertifolia on Human Breast and Cervical Cancer Cells." BYU ScholarsArchive, 2008. https://scholarsarchive.byu.edu/etd/1703.
Повний текст джерелаPéladeau, Christine. "Utrophin A Upregulation by FDA-Approved Drugs for the Treatment of Duchenne Muscular Dystrophy." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39298.
Повний текст джерелаAlqahtani, Saad Mohammed S. "Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study." University of Toledo / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1493378726116385.
Повний текст джерелаFan, Ya-Wen, and 范雅雯. "The effect and molecular action of curcumin in FDA-approved clinical drug-treated human bladder cancer cells." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/63474138092702105330.
Повний текст джерела國立臺灣師範大學
人類發展與家庭學系
102
Bladder cancer is the ninth most common cancer worldwide and the fourteenth most diagnosed malignancy in Taiwan (2013). Gemcitabine plus cisplatin (GC) treatment is prefered for nowadays treatment. For patients with impaired renal function, gemcitabine plus carboplatin (GCa) treatment is recommended. Overexpressions of Aurora A kinase and epidermal growth factor (EGF) were observed in bladder cancer cells. Our previously data demonstrate that curcumin significantly inhibited Aurora A gene expression, in part caused failure of various mitotic events and G2/M arrest of human bladder cancer cells. In this study, human bladder cancer T24 cells were treated with the existing chemotherapy (GC or GCa) in the presence and absence of curcumin. Addition of curcumin not only produced synergism using combination index analysis, but also raised the percentages of phases in sub-G1 (apoptosis rate) and G2/M using flow cytometry. Combinatio of cucurmin induced autophagy. Decreasing of phospho-Aurora A, p62, Beclin-1, phospho-PI3K, phospho-p70s6k, Atg12-Atg5 and increasing of LC3-II, phospho-mTOR, phospho-AKT, phospho-MEK, phospho-ERK were observed. Taken together, clinical drugs combined with curcumin not only inhibited activity of aurora a, but also promoted apoptosis and autophagy in T24 cells.
(8803004), Logan C. Ganzen. "Drug Screening Utilizing the Visual Motor Response of a Zebrafish Model of Retinitis Pigmentosa." Thesis, 2020.
Знайти повний текст джерелаChang, En-Kai, and 張恩愷. "Combinatorial effects of six FDA approved drugs on influenza virus." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/3272nt.
Повний текст джерела國立陽明大學
微生物及免疫學研究所
106
英文摘要 Influenza virus belongs to Orthomyxoviridae. Influenza spreads around the world yearly, resulting in about three to five million cases of severe illness and about 250,000 to 500,000 deaths. The only drugs currently available to treat influenza are neuraminidase ( NA ) inhibitors,including oseltamivir ( Tamiflu ), zanamivir and peramivir, and an RNA-dependent RNA polymerase ( RdRp ) inhibitor, favipiravir ( Avigan ). Since influenza virus RdRp lacks proofreading activity, the genome is easy to mutate when replicating. As a result, drug resistance and limited vaccine protection occur. In this project, we hope to repurpose FDA-proved drugs for treating influenza. As to all viruses, influenza virus depends heavily on cellular mechanism to complete its life cycle. If inhibited cellular factors mediate the antiviral effects ( cellular factor-targeting ), drug-resistant influenza viruses may not be selected easily by cellular factor-targeting drugs as compared to virus-targeting drugs. Previously our lab used RdRp reporter assay to screen drugs, and found six drugs may inhibit influenza virus infection. All six drugs are generic drugs. Here I looked for combinations with synergistic anti-viral effects even at low drug dosages. A lower drug dosage will assert lower selection pressure on influenza virus and less cytotoxicity on host. In addition, treatment with multiple drugs decrease the possibility of drug-resistant viruses. First, the CC50 and IC50 of each of these six drugs were determind on MDCK and influenza-infected MDCK cells, respectively. Therapeutic index for each compound was calculated. Four out of six drugs tested were found to inhibit influenza virus replication by itself. Next, all of the binary and ternary combinations were tested, which concluded that a particular binary combination is most effective. In order to identify the likely steps suppressed by this combination, I added the drug combination at different time points post infection in time course assays and found that combination inhibited at early stage of the infection cycle. The results of hemagglutinin assay excluded that the combination inhibited HA protein binding to its receptor. Instead, the preliminary results supported that the combination acts on the step prior to viral RNP into cell nucleus. Testing the anti-viral ability of the combination on an animal model will further demonstrate its efficacy and potential in the future.
"Lead Identification, Optimization and Characterization of Novel Cancer Treatment Strategies Using Repositioned Drugs." Doctoral diss., 2013. http://hdl.handle.net/2286/R.I.18035.
Повний текст джерелаDissertation/Thesis
Ph.D. Chemical Engineering 2013
Wu, Chi-Shiuan, and 吳奇軒. "The role of KRAS gene in combination treatment of Curcumin and FDA-approved Targeted Drugs in human colorectal cancer cells." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/69752446398460271062.
Повний текст джерелаКниги з теми "FDA-approved drug"
United States. Food and Drug Administration, ed. FDA Approved Animal Drug Products, 1998. [S.l: s.n., 1998.
Знайти повний текст джерелаUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2nd ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Знайти повний текст джерелаR, Loughlin Kevin, and Generali Joyce A, eds. The guide to off-label prescription drugs: New uses for FDA-approved prescription drugs. New York: Free Press, 2006.
Знайти повний текст джерелаMeridia: The weight-loss breakthrough : everything you need to know about the FDA-approved weight-loss pill. Rocklin, CA: Prima Health, 1998.
Знайти повний текст джерелаUnited States. Dept. of Defense. Office of the Secretary of Defense. and National Defense Research Institute (U.S.), eds. Military use of drugs not yet approved by the FDA for CW/BW defense: Lessons from the Gulf War. Santa Monica, CA: RAND, 1999.
Знайти повний текст джерелаCourtney, Charles H. Veterinary antiparasitic drugs 1991: A comprehensive compendium of FDA-approved antiparasitic drugs. Gainesville, Fla: Institute of Food and Agricultural Sciences, University of Florida, 1991.
Знайти повний текст джерелаUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2nd ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Знайти повний текст джерелаUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2nd ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Знайти повний текст джерелаUnited States. Food and Drug Administration. Office of Public Affairs, ed. FDA-approved bargain drugs: Generic products must meet high standards. 2nd ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Знайти повний текст джерелаUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2nd ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Знайти повний текст джерелаЧастини книг з теми "FDA-approved drug"
Rehman, Nahid, and Anjana Pandey. "Nanomedicine Approved by FDA and EMEA." In Engineered Nanoparticles as Drug Delivery Systems, 79–90. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003252122-8.
Повний текст джерелаHassan, Mubashir, Saba Shahzadi, and Andrzej Kloczkowski. "Pharmacoinformatic Analysis of Drug Leads for Alzheimer’s Disease from FDA-Approved Dataset Through Drug Repositioning Studies." In Bioinformatics and Biomedical Engineering, 191–201. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-34953-9_15.
Повний текст джерелаBarenholz, Yechezkel (Chezy). "Chapter 13. Doxil® – the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical Use." In Drug Discovery, 315–45. Cambridge: Royal Society of Chemistry, 2016. http://dx.doi.org/10.1039/9781782622536-00315.
Повний текст джерелаMitra, Debanjan, and Pradeep K. Das Mohapatra. "Computational Intelligence in Identification of Some FDA Approved Drug Compounds for Treatment of COVID-19." In Artificial Intelligence and Machine Learning Methods in COVID-19 and Related Health Diseases, 109–22. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04597-4_5.
Повний текст джерелаGan, Julian, Jong Hyun Cho, Ryan Lee, Alireza Naghizadeh, Ling Yue Poon, Ethan Wang, Zachary Hui, and Dongfang Liu. "Methods of Machine Learning-Based Chimeric Antigen Receptor Immunological Synapse Quality Quantification." In The Immune Synapse, 493–502. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3135-5_32.
Повний текст джерелаKim, Hahnsung, Yin Wu, Daisy Villano, Dario Livio Longo, Michael T. McMahon, and Phillip Zhe Sun. "Analysis Protocol for the Quantification of Renal pH Using Chemical Exchange Saturation Transfer (CEST) MRI." In Methods in Molecular Biology, 667–88. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-0978-1_40.
Повний текст джерелаScott, Kevin A., and Jon T. Njardarson. "Analysis of US FDA-Approved Drugs Containing Sulfur Atoms." In Sulfur Chemistry, 1–34. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-25598-5_1.
Повний текст джерелаPéladeau, Christine, and Bernard J. Jasmin. "Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy." In Methods in Molecular Biology, 495–510. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2772-3_26.
Повний текст джерелаLópez-Márquez, Arístides, Ainhoa Martínez-Pizarro, Belén Pérez, Eva Richard, and Lourdes R. Desviat. "Modeling Splicing Variants Amenable to Antisense Therapy by Use of CRISPR-Cas9-Based Gene Editing in HepG2 Cells." In Methods in Molecular Biology, 167–84. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2010-6_10.
Повний текст джерелаAbou-el-Enein, Mohamed, and Jordan Gauthier. "The Value of CAR-T-cell Immunotherapy in Cancer." In The EBMT/EHA CAR-T Cell Handbook, 231–34. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_46.
Повний текст джерелаТези доповідей конференцій з теми "FDA-approved drug"
Raynal, Noël J., Justin T. Lee, Youjun Wang, Judith Garriga, Gabriel Malouf, Sarah Dumont, Elisha J. Dettman, et al. "Abstract 380: Discovery of new epigenetic drugs among FDA-approved drug libraries." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-380.
Повний текст джерелаGanapathy, Vadivel, Ellappan Babu, Sabarish Ramachandran, and Yangzom D. Bhutia. "Abstract 1015: Repurposing the FDA-approved drug carbidopa to treat human cancers." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1015.
Повний текст джерелаTatman, Philip, Anthony Fringuello, Denise Damek, Samy Youssef, Randy Jensn, Kevin Lillehei, and Michael Graner. "High-Throughput Drug Screening of FDA-Approved Cancer Drugs Reveals Novel Therapies for Patients with Chordomas." In 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679578.
Повний текст джерелаGupta, Nancy Sanjay, and Pravir Kumar. "TDP-43 Inhibitors in Amyotrophic Lateral Sclerosis: An Application of Drug Repurposing Approach Using FDA-Approved Drugs." In 2023 International Conference on Computational Intelligence and Sustainable Engineering Solutions (CISES). IEEE, 2023. http://dx.doi.org/10.1109/cises58720.2023.10183592.
Повний текст джерелаDing, Andy S., Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli, and Betty Tyler. "Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2190.
Повний текст джерелаDing, Andy S., Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli, and Betty Tyler. "Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2190.
Повний текст джерелаHuq, Sakibul, Joshua Casaos, Michael Peters, Yuanxuan Xia, Andy Ding, Manuel Morales, Noah Gorelick, et al. "Abstract B06: Repositioning the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma." In Abstracts: AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 29-30, 2019; Austin, TX. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.aacrahns19-b06.
Повний текст джерелаMitash, N., H. N. Alsafadi, R. H. Pineda, K. Kohler, M. Ishizuka, J. Sembrat, M. Lehmann, R. Chambers, D. E. Wagner, and M. Koenigshoff. "Inhibition of YAP/TAZ Signaling by the FDA Approved Drug Verteporfin Attenuates Fibrosis in Mouse and Human Tissue." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5226.
Повний текст джерелаSenbabaoglu, Filiz, Ahmet Cingöz, Ezgi Kaya, Selena Kazancioglu, Nathan Alan Lack, Ceyda Acilan, and Tugba Bagci-Onder. "Abstract B73: Screen among 1200 FDA-approved drug library reveals mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-b73.
Повний текст джерелаSchultz, Christopher W., Teena Dhir, Samantha Z. Brown, Saswati Chand, Wei Jiang, Grace A. McCarthy, Alex O. Haber, et al. "Abstract 3058: Recharacterizing the FDA approved drug pyrvinium pamoate as a clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3058.
Повний текст джерелаЗвіти організацій з теми "FDA-approved drug"
Matthews, Lisa, Guanming Wu, Robin Haw, Timothy Brunson, Nasim Sanati, Solomon Shorser, Deidre Beavers, Patrick Conley, Lincoln Stein, and Peter D'Eustachio. Illuminating Dark Proteins using Reactome Pathways. Reactome, October 2022. http://dx.doi.org/10.3180/poster/20221027matthews.
Повний текст джерелаScreening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity. EMBL-EBI, March 2022. http://dx.doi.org/10.6019/chembl4651402.
Повний текст джерела